natgillin/translations-raw huggingface dataset:
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
Nakon što počnete s liječenjem Vaše HIV infekcije, osim oportunističkih infekcija, mogu se pojaviti autoimune bolesti (stanje koje nastaje kad imunološki sustav napada zdrava tjelesna tkiva).
The M184I/V substitution emerged in 5/26 Atazanavir /ritonavir and 7/26 lopinavir/ritonavir virologic failure patients, respectively. 
Supstitucija M184I/V bila je prisutna u 5 od 26 bolesnika u kojih liječenje atazanavirom s ritonavirom nije bilo virološki uspješno i 7 od 26 bolesnika u kojih liječenje lopinavirom/ritonavirom nije bilo virološki uspješno.
If signs or symptoms of cholelithiasis occur, temporary interruption or discontinuation of treatment may be considered. 
Ako se pojave znakovi i simptomi kolelitijaze, može se razmotriti privremeni ili trajni prekid liječenja.
The mean baseline CD4 cell count was 337 cells/mm 
Prosječni početni broj CD4 stanica iznosio je 337 stanica/mm
HDPE bottle with polypropylene screw cap containing 60 capsules. 
Boca od polietilena visoke gustoće (HDPE) s navojnim čepom od polipropilena koja sadrži 60 kapsula.
Co-administration of simvastatin or lovastatin with atazanavir is contraindicated due to an increased risk of myopathy including rhabdomyolysis (see section 4.3). 
Kontraindicirana je istovremena primjena simvastatina ili lovastatina s atazanavirom zbog povišenog rizika od miopatije uključujući rabdomiolizu (vidjeti dio 4.3).
Therapy should be initiated by a physician experienced in the management of HIV infection. 
4.2 Doziranje i način primjene Terapiju treba započeti liječnik s iskustvom u liječenju HIV-infekcije.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with atazanavir may result in increased concentrations. 
Metabolizam simvastatina i lovastatina jako ovisi o enzimu CYP3A4 i istovremena primjena s atazanavirom može rezultirati povišenim koncentracijama.
Six of 20 (30%) women on atazanavir/ritonavir 300/100 mg and 13 of 21 (62%) women on atazanavir /ritonavir 400/100 mg experienced grades 3 to 4 hyperbilirubinaemia. 
Šest od 20 (30%) žena koje su primale atazanavir/ritonavir 300/100 mg i 13 od 21 (62%) žene koje su primale atazanavir/ritonavir 400/100 mg razvilo je hiperbilirubinemiju 3. do 4. stupnja.
In the majority of patients with at least one functional CYP2C19 allele, a reduction in both voriconazole and atazanavir exposures are expected. 
U većine bolesnika s najmanje jednim funkcionalnim CYP2C19 alelom očekuje se smanjenje izloženosti kako vorikonazolu tako i atazanaviru.
Co-administration of Atazanavir Mylan with these medicinal products is expected to substantially increase their concentrations and may result in PDE5-associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5). 
Pri istovremenoj primjeni lijeka Atazanavir Mylan i ovih lijekova očekuje se znatno povećanje njihove koncentracije, što može rezultirati nuspojavama povezanima s PDE5, kao što su hipotenzija, poremećaji vida i prijapizam (vidjeti dio 4.5).
30 hard capsules 60 hard capsules. 
30 hard capsules 60 tvrdih kapsula.
When atazanavir and ritonavir are co-administered, the metabolic drug interaction profile for ritonavir may predominate because ritonavir is a more potent CYP3A4 inhibitor than atazanavir. 
Kod istovremene primjene atazanavira i ritonavira može prevladavati metabolički profil interakcija za ritonavir, zato što je ritonavir jači inhibitor enzima CYP3A4 od atazanavira.
Among experienced patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 95 weeks, 53% had Grade 3-4 total bilirubin elevations. 
Među prethodno liječenim bolesnicima koji su primali atazanavir 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan tijekom srednjeg razdoblja od 95 tjedana, 53% imalo je povišenje ukupnog bilirubina 3.-4. stupnja.
Concomitant use of Atazanavir Mylan/ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section 4.5). 
Ne preporučuje se istovremena primjena lijeka Atazanavir Mylan s ritonavirom i flutikazona ili drugih kortikosteroida koje metabolizira enzim CYP3A4, osim ako je moguća korist liječenja veća od rizika od učinaka sistemskih kortikosteroida, uključujući Cushingov sindrom i supresiju nadbubrežne žlijezde (vidjeti dio 4.5).
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5). 
Istovremena primjena s lijekovima koji su supstrati izoenzima CYP3A4 citokroma P450 i imaju uzak terapijski raspon (npr. kvetiapin, lurasidon, alfuzozin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralno primijenjen midazolam (za mjere opreza kod parenteralno primijenjenog midazolama, vidjeti dio 4.5) i alkaloidi ergota, osobito ergotamin, dihidroergotamin, ergonovin, metilergonovin) (vidjeti dio 4.5).
Didanosine Cmin ↑25% (↓8% ↑69%) 
Didanozin Cmin ↑25% (↓8% ↑69%)
Voriconazole AUC ↑561% (↑451% 
Vorikonazol AUC ↑561% (↑451%
If the combination of Atazanavir Mylan with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded. 
Ako se prosudi da je kombinacija lijeka Atazanavir Mylan s inhibitorom protonske pumpe neizbježna, preporučuje se pažljiv klinički nadzor u kombinaciji s povišenjem doze atazanavira na 400 mg uz 100 mg ritonavira; ne smije se prekoračiti doza inhibitora protonske pumpe koja je usporediva s dozom omeprazola od 20 mg.
, angioedema a, urticaria, alopecia, pruritus; rare: Stevens-Johnson syndrome a,b 
pruritus; rijetko: Stevens-Johnsonov sindrom a,b
An initial dose reduction of diltiazem by 50% is recommended, with subsequent 
Preporučuje se smanjenje početne doze diltiazema za 50%, uz kasniju titraciju po potrebi i elektrokardiografski nadzor.
Patients should be informed that dizziness has been reported during treatment with regimens containing atazanavir (see section 4.8). 
Bolesnike treba obavijestiti da je tijekom liječenja protokolima koji sadrže atazanavir zabilježena omaglica (vidjeti dio 4.8).
This decrease in atazanavir Cmin, might negatively impact the efficacy of atazanavir. 
Ovo sniženje Cmin atazanavira može negativno utjecati na djelotvornost atazanavira.
What Atazanavir Mylan contains 
Što Atazanavir Mylan sadrži
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA <400 copies/ml (<50 copies/ml) for atazanavir + ritonavir were 84% (72%) and for lopinavir + ritonavir were 82% (72%). 
Analizom prema liječenju, isključujući vrijednosti koje su nedostajale, udio bolesnika s HIV RNK <400 kopija/ml (<50 kopija/ml) u skupini koja je primala atazanavir s ritonavirom iznosio je 84% (72%), a u skupini koja je primala lopinavir s ritonavirom 82% (72%).
Unboosted atazanavir must not be used in patients with severe hepatic impairment. 
Nepojačani atazanavir ne smije se primjenjivati u bolesnika s teškim oštećenjem funkcije jetre.
In HIV-infected adult patients (n=33, combined studies) the mean half-life within a dosing interval for atazanavir was 12 hours at steady state following a dose of 300 mg daily with ritonavir 100 mg once daily with a light meal. 
U odraslih bolesnika zaraženih HIV-om (n=33, kombinirana ispitivanja), prosječni poluvijek unutar intervala doziranja atazanavira iznosio je 12 sati u stanju dinamičke ravnoteže nakon doze od 300 mg na dan zajedno s ritonavirom u dozi od 100 mg jedanput na dan, uz lagani obrok.
Ethinyloestradiol Cmin ↑91% (↑57% 
Etinilestradiol Cmin ↑91% (↑57%
EU/1/16/1091/001 EU/1/16/1091/002 EU/1/16/1091/003 EU/1/16/1091/004 EU/1/16/1091/005 EU/1/16/1091/006 EU/1/16/1091/007 EU/1/16/1091/008 EU/1/16/1091/009 EU/1/16/1091/010 EU/1/16/1091/011 EU/1/16/1091/012 EU/1/16/1091/013 EU/1/16/1091/014 EU/1/16/1091/015 EU/1/16/1091/016 EU/1/16/1091/017 
EU/1/16/1091/001 EU/1/16/1091/002 EU/1/16/1091/003 EU/1/16/1091/004 EU/1/16/1091/005 EU/1/16/1091/006 EU/1/16/1091/007 EU/1/16/1091/008 EU/1/16/1091/009 EU/1/16/1091/010 EU/1/16/1091/011 EU/1/16/1091/012 EU/1/16/1091/013 EU/1/16/1091/014 EU/1/16/1091/015 EU/1/16/1091/016
Didanosine (enteric coated capsules) 400 mg single dose 
Didanozin (želučanootporne kapsule) 400 mg, jednokratna doza
No significant effect on didanosine and stavudine concentrations was observed. 
Nije opažen značajan učinak na koncentracije didanozina i stavudina.
Geometric mean (CV%) AUC ng•h/mL 
Geometrijska sredina (CV%) AUC ng•h/mL Geometrijska sredina (CV%) Cmin ng/mL
All patients HIV RNA <400 copies/ml, % 
Svi bolesnici HIV RNK <400 kopija/ml, %
• asthenia (unusual tiredness or weakness) 
• astenija (neobičan umor ili slabost)
Norethindrone Cmax ↑67% (↑42% 
Noretindron Cmax ↑67% (↑42%
Co-administration of Atazanavir Mylan and medicinal products that induce CYP3A4 is not recommended (see sections 4.3 and 4.5). 
Ne preporučuje se istovremena primjena lijeka Atazanavir Mylan i lijekova koji induciraju CYP3A4 (vidjeti dijelove 4.3 i 4.5).
No drug interaction study has been performed for the co-administration of atazanavir with benzodiazepines. 
Nisu provedena ispitivanja interakcija lijekova kod istovremene primjene atazanavira i benzodiazepina.
Titanium dioxide (E171) Indigo Carmine (E132) Gelatin 
Titanijev dioksid (E171) Indigo karmin (E132) Želatina
Voriconazole Cmin ↑765% (↑571% 
Vorikonazol Cmin ↑765% (↑571%
14-OH clarithromycin Cmin ↓62% 
14-OH klaritromicin Cmin ↓62%
14-OH clarithromycin Cmax ↓72% 
14-OH klaritromicin Cmax ↓72%
36 (43/120) 32 (38/120) 42 (52/123)_ 35 (41/118) NA 
(bolesnici s odgovorom/bolesnici koji su se mogli procijeniti) Svi bolesnici 36 (43/120) 32 (38/120) 42 (52/123 35 (41/118) NP
In a small number of patients without a functional CYP2C19 allele, significantly increased voriconazole exposures are expected. 
U malog broja bolesnika bez funkcionalnog CYP2C19 alela očekuje se značajno povećanje izloženosti vorikonazolu.
The concomitant use of quinidine is contraindicated (see section 4.3). 
Istovremena primjena kinidina je kontraindicirana (vidjeti dio 4.3).
Both asymptomatic first-degree (23%) and second-degree (1%) atrioventricular block were reported in paediatric patients. 
U pedijatrijskih je bolesnika bio zabilježen i asimptomatski atrioventrikularni blok prvog (23%) ili drugog stupnja (1%).
Propylene glycol Ammonia solution, concentrated Iron oxide black (E172) Potassium hydroxide 
Otopina amonijaka, koncentrirana Crni željezov oksid (E172) Kalijev hidroksid
Atazanavir + saquinavir was shown to be inferior to lopinavir + ritonavir. 
Pokazalo se da je atazanavir sa sakvinavirom inferioran kombinaciji lopinavira s ritonavirom.
The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with H2-blockers. 
Mehanizam interakcije je smanjenje topljivosti atazanavira s povećanjem želučanog pH zbog H2 blokatora.
Tell your doctor if you notice anything unusual about your health. 
Ako primijetite nešto neobično u vezi sa svojim zdravljem, obavijestite o tome
(range: 100 to 1157 cells/ mm 3) and mean baseline plasma HIV 1 RNA was 4.09 log10 copies/ml (range: 3.28 to 5.00 log10 copies/ml). 
(raspon: 100 do 1157 stanica/ mm 3), a prosječna početna vrijednost HIV 1 RNK u plazmi iznosila je 4,09 log10 kopija/ml (raspon: 3,28 do 5,00 log10 kopija/ml).
3rd Trimester (n=20) 
3. tromjesečje (n=20)
When co-administered with tenofovir disoproxil fumarate, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg and tenofovir disoproxil fumarate 300 mg (all as a single dose with food). 
Kada se atazanavir primjenjuje istovremeno s tenofovirdizoproksilfumaratom, preporučuje se primijeniti 300 mg atanazavira sa 100 mg ritonavira i 300 mg tenofovirdizoproksilfumarata (svi se primjenjuju kao jednokratna doza s hranom).
Atazanavir Mylan contains lactose 
Atazanavir Mylan sadrži laktozu
Among naive patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 96 weeks, 48% had Grade 3-4 total bilirubin elevations (see section 4.4). 
Među bolesnicima koji prethodno nisu bili liječeni i primali su atazanavir 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan tijekom srednjeg razdoblja od 96 tjedana, 48% imalo je povišenje ukupnog bilirubina 3.-4. stupnja (vidjeti dio 4.4).
- in patients without a functional CYP2C19 allele, close clinical and laboratory monitoring of voriconazole-associated adverse events is recommended 
- za bolesnike bez funkcionalnog CYP2C19 alela preporučuje se poman nadzor kliničkih i laboratorijskih parametara koji upućuju na nuspojave povezane s vorikonazolom
postpartum a 
Nakon porođaja a
The pharmacokinetics of atazanavir exhibit a non-linear disposition. 
Farmakokinetika atazanavira pokazuje nelinearni oblik.
* When compared to atazanavir 300 mg and ritonavir 100 mg without nevirapine. 
* Kad se uspoređivao s atazanavirom 300 mg i ritonavirom 100 mg bez nevirapina.
(atazanavir 400 mg single dose) 
(atazanavir 400 mg, jednokratna doza)
Frequency de novo PI substitution (n=35) 
Učestalost de novo supstitucije za rezistenciju na inhibitor proteaze (n=35)
Concentrations of these immunosuppressants may be increased when co-administered with atazanavir due to CYP3A4 inhibition. 
Koncentracije ovih imunosupresiva mogu biti povišene kad se primjenjuju istovremeno s atazanavirom zbog inhibicije CYP3A4.
a none none a 
a nijedna 10-20% nijedna a
Norethindrone AUC ↑110% (↑68% 
Noretindron AUC ↑110% (↑68%
In HIV-infected patients (n=33, combined studies), multiple dosing of atazanavir 300 mg once daily with ritonavir 100 mg once daily with food produced a geometric mean (CV%) for atazanavir, Cmax of 4466 (42%) ng/ml, with time to Cmax of approximately 2.5 hours. 
U bolesnika zaraženih HIV-om (n=33, kombinirana ispitivanja), višestruka primjena atazanavira 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan s hranom dovela je do geometrijske sredine (CV%) Cmax atazanavira od 4466 (42%) ng/ml, uz vrijeme do postizanja Cmax od približno 2,5 sati.
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA < 400 copies/ml (< 50 copies/ml) in the atazanavir + ritonavir arm and the lopinavir + ritonavir arm were 55% (40%) and 56% (46%), respectively. 
Analizom prema liječenju, isključujući vrijednosti koje su nedostajale, udio bolesnika s HIV RNK < 400 kopija/ml (< 50 kopija/ml) u skupini koja je primala atazanavir s ritonavirom iznosio je 55% (40%), a u skupini koja je primala lopinavir s ritonavirom 56% (46%).
Co-administration with atazanavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-associated adverse events, including hypotension, visual changes, and priapism. 
Istovremena primjena s atazanavirom može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s PDE5, uključujući hipotenziju, poremećaje vida i prijapizam.
Through 48 weeks of treatment, the mean changes from baseline in HIV RNA levels for atazanavir + ritonavir and lopinavir + ritonavir were similar (non-inferior). 
Nakon 48 tjedana liječenja, prosječna promjena razine HIV RNK u odnosu na početnu vrijednost uz atazanavir s ritonavirom bila je slična (neinferiorna) onoj uz lopinavir s ritonavirom.
No dose adjustment is needed for atazanavir. 
Nije potrebna prilagodba doze atazanavira.
• oedema (swelling) 
• edemi (oticanje)
Study 045 is a randomised, multicenter trial comparing atazanavir /ritonavir (300/100 mg once daily) and atazanavir /saquinavir (400/1,200 mg once daily), to lopinavir + ritonavir (400/100 mg fixed dose combination twice daily), each in combination with tenofovir disoproxil fumarate (see sections 4.5 and 4.8) and one NRTI, in patients with virologic failure on two or more prior regimens containing at least one PI, NRTI, and NNRTI. 
Ispitivanje 045 randomizirano je, multicentrično ispitivanje u kojem su atazanavir/ritonavir (300/100 mg jedanput na dan) i atazanavir/sakvinavir (400/1200 mg jedanput na dan) uspoređivani s lopinavirom + ritonavirom (400/100 mg, fiksna kombinacija doza, dvaput na dan), a svaka se od tih terapija primjenjivala u kombinaciji s tenofovirdizoproksilfumaratom (vidjeti dijelove 4.5 i 4.8) i jednim NRTI-jem u bolesnika u kojih je dva ili više prethodnih protokola s najmanje jednim inhibitorom proteaze, NRTI-jem i NNRTI-jem bilo virološki neuspješno.
The recommended dose of atazanavir is 300 mg once daily taken with ritonavir 100 mg once daily and with food. 
Preporučena doza atazanavira je 300 mg jedanput na dan i uzima se s ritonavirom u dozi od 100 mg jedanput na dan i s hranom.
Co-administration of atazanavir with ritonavir and proton pump inhibitors is not recommended. 
Ne preporučuje se istovremena primjena atazanavira s ritonavirom i inhibitorima protonske pumpe.
Study 138 is an international randomised, open-label, multicenter, prospective trial of treatment naïve patients comparing atazanavir/ritonavir (300 mg/100 mg once daily) to lopinavir/ritonavir (400 mg/100 mg twice daily), each in combination with fixed dose tenofovir disoproxil fumarate/emtricitabine (300 mg/200 mg tablets once daily). 
Ispitivanje 138 međunarodno je, randomizirano, multicentrično, prospektivno ispitivanje otvorenog tipa u bolesnika koji prethodno nisu bili liječeni u kojem se atazanavir/ritonavir (300 mg/100 mg jedanput na dan) uspoređivao s lopinavirom/ritonavirom (400 mg/100 mg dvaput na dan), gdje su obje te kombinacije bile davane zajedno s fiksnom dozom tenofovirdizoproksilfumarata/emtricitabina (300 mg/200 mg tablete, jedanput na dan).
Skin and subcutaneous tissue disorders: common: rash; uncommon: erythemia multiforme a,b 
često: osip; manje često: multiformni eritem a,b
HIV RNA <50 copies/ml, % 
HIV RNK <50 kopija/ml, %
HIV RNA <50 copies/ml by select baseline PI substitutions, 
b) HIV RNK <50 kopija/ml prema početnim odabranim supstitucijama za rezistenciju na inhibitor proteaze,
If the co-administration of Atazanavir Mylan with an NNRTI is required, an increase in the dose of both Atazanavir Mylan and ritonavir to 400 mg and 200 mg, respectively, in combination with efavirenz could be considered with close clinical monitoring. 
Ako je potrebno istovremeno primjenjivati Atazanavir Mylan s nekim NNRTI-jem, može se razmotriti povišenje doze lijeka Atazanavir Mylan na 400 mg i ritonavira na 200 mg u kombinaciji s efavirenzom, uz pažljivo praćenje bolesnika.
Proton pump inhibitors Omeprazole 40 mg once daily 
Inhibitori protonske pumpe Omeprazol 40 mg jedanput na dan
(400 mg/100 mg twice daily) n=443 
(400 mg/100 mg dvaput na dan) n=443
The combination of rifampicin and atazanavir is contraindicated (see section 4.3). 
Kombinacija rifampicina i atazanavira je kontraindicirana (vidjeti dio 4.3).
Additional minor metabolic pathways consist of 
Dodatni manji metabolički putovi sastoje se od N-dezalkilacije i hidrolize.
Concomitant use of St. John's wort with atazanavir may be expected to result in significant reduction in plasma levels of atazanavir. 
Može se očekivati da istovremena primjena gospine trave i atazanavira rezultira značajnim sniženjem razine atazanavira u plazmi.
Ethinyloestradiol Cmin ↓37% (↓45% 
Etinilestradiol Cmin ↓37% (↓45%
common: jaundice; uncommon: hepatitis, cholelithiasis a, cholestasis a; 
često: žutica; manje često: hepatitis, kolelitijaza a, kolestaza a;
Indinavir is associated with indirect unconjugated hyperbilirubinaemia due to inhibition of UGT. 
Indinavir je povezan s indirektnom hiperbilirubinemijom zbog povišenja nekonjugiranog bilirubina, što je posljedica inhibicije UGT.
Lamotrigine should be used with caution in combination with atazanavir/ritonavir. 
Lamotrigin se mora primjenjivati uz oprez u kombinaciji s atazanavirom i ritonavirom.
There was less hyperbilirubinaemia and jaundice in the unboosted atazanavir group compared with the atazanavir + ritonavir group (18 and 28 subjects, respectively). 
U skupini liječenoj nepojačanim atazanavirom zabilježeno je manje slučajeva hiperbilirubinemije i žutice nego u skupini koja je primala atazanavir + ritonavir (18 naspram 28 ispitanika).
6.5 Nature and contents of container 
6.5 Vrsta i sadržaj spremnika 150 mg
Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 4.3). 
Atazanavir se prvenstveno metabolizira u jetri, pa su u bolesnika s oštećenjem jetre bile opažene povišene koncentracije atazanavira u plazmi (vidjeti dijelove 4.2 i 4.3).
Due to CYP3A4 inhibition by atazanavir, concentrations of quetiapine are expected to increase. 
Budući da atazanavir inhibira CYP3A4, očekuje se povećanje koncentracija kvetiapina.
* When compared to atazanavir 300 mg once daily with ritonavir 100 mg once daily and tenofovir disoproxil fumarate 300 mg all as a single dose with food. 
* Kad se uspoređuje s atazanavirom 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan i tenofovirdizoproksilfumaratom 300 mg, svi primijenjeni kao jednokratna doza s hranom.
Atazanavir with ritonavir has not been studied in patients with hepatic impairment. 
Atazanavir s ritonavirom nije ispitan u bolesnika s oštećenjem funkcije jetre.
150 mg capsules 
150 mg kapsule
Antiretroviral treatment experienced adult patients 
Antiretrovirusno liječenje prethodno liječenih bolesnika
Reversible elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT) have occurred in patients receiving atazanavir (see section 4.8). 
U bolesnika koji su primali atazanavir nastupilo je reverzibilno povišenje indirektnog (nekonjugiranog) bilirubina povezano s inhibicijom UDP-glukuronozil transferaze (UGT) (vidjeti dio 4.8).
60 x 1 hard capsules. 
60 x 1 tvrda kapsula.
• muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) 
• mišićna atrofija (gubitak mišića), artralgija (bol u zglobovima), mialgija (bol u mišićima)
Serious skin rash, including Stevens-Johnson syndrome, has been reported in patients taking atazanavir. 
U bolesnika koji uzimaju atazanavir zabilježen je ozbiljni kožni osip, uključujući Stevens-Johnsonov sindrom.
Tenofovir disoproxil fumarate 300 mg once daily 
Tenofovirdizoproksilfumarat 300 mg jedanput na dan
The frequency of treatment emergent hepatitis or transaminase elevations in co-infected patients was comparable between atazanavir and comparator regimens (see section 4.4). 
Učestalost hepatitisa ili povišenja transaminaza koji su se u bolesnika s istovremenim infekcijama razvili tijekom liječenja atazanavir bila je slična onoj pri primjeni komparatorskih protokola (vidjeti dio 4.4).
The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or ritonavir. 
Mehanizam interakcije je inhibicija enzima CYP3A4 atazanavirom i/ili ritonavirom.
Chronic kidney disease 
Kronična bubrežna bolest
Voriconazole AUC ↓33% (↓42% 
Vorikonazol AUC ↓33% (↓42%
Combinations of atazanavir and indinavir have not been studied and co-administration of these medicinal products is not recommended (see section 4.5). 
Kombinacije atazanavira i indinavira nisu ispitane pa se ne preporučuje njihova istovremena primjena (vidjeti dio 4.5).